YTHDF1 and neoplasm: YTHDF1/2/3 promote prostate cancer proliferation, invasion and metastasis and suppress anti-tumor immunity by different mechanisms (Li et al., 2020[128], 2022[132]; Duan et al., 2024[53]; Wang et al., 2024[277]).